A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
about
A Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionEmerging monoclonal antibodies against Clostridium difficile infection.A camelid single-domain antibody neutralizes botulinum neurotoxin A by blocking host receptor binding.Genetically engineered red cells expressing single domain camelid antibodies confer long-term protection against botulinum neurotoxin.
P2860
A Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@en
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@nl
type
label
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@en
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@nl
prefLabel
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@en
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@nl
P2093
P2860
P356
P1476
A Tetraspecific VHH-Based Neut ...... ostridium difficile Infection.
@en
P2093
Charles B Shoemaker
Diane J Schmidt
Elena A Kashentseva
Gillian Beamer
Hyeun Bum Kim
Igor P Dmitriev
Jacqueline M Tremblay
Jennifer A Steele
Michele Debatis
Xingmin Sun
P2860
P304
P356
10.1128/CVI.00730-15
P577
2016-07-13T00:00:00Z